BioTime Wins Grant

BioTime said Monday it has been awarded a new grant for 2017 of up to ILS7.2 million ($2 million) from the Israel Innovation Authority (IIA) for the continued development of OpRegen, which is being studied for the treatment of the dry form of age-related macular degeneration (AMD).

OpRegen is currently in a phase 1/2a dose-optimization clinical study, which in July received authorization from the data safety monitoring board to move forward with enrollment of cohort 3. In cohort 3, BioTime said it plans to treat patients at sites in Israel and the U.S. To date BioTime said the IIA has provided annual grants totaling approximately $12 million.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Comment